ライフサイエンスコーパス: dermatomyositis

1 nflammatory myopathy (i.e., polymyositis and dermatomyositis).

2 human autoimmune settings including juvenile dermatomyositis.

3 tissue of adult dermatomyositis and juvenile dermatomyositis.

4 ontributions to the pathogenesis of juvenile dermatomyositis.

5 e type 1 interferon pathway for treatment of dermatomyositis.

6 rse effects in patients with polymyositis or dermatomyositis.

7 ts, 54 with inflammatory myopathies, 14 with dermatomyositis.

8 juvenile idiopathic arthritis, and juvenile dermatomyositis.

9 losporin in children with new-onset juvenile dermatomyositis.

10 inent data from adults with polymyositis and dermatomyositis.

11 c control of the immune response in juvenile dermatomyositis.

12 perimysial blood vessels in 10 patients with dermatomyositis.

13 small vessel occlusion in untreated juvenile dermatomyositis.

14 ear cells from children with active juvenile dermatomyositis.

15 d genetics play in the evolution of juvenile dermatomyositis.

16 derstanding the etiopathogenesis of juvenile dermatomyositis.

17 disability for adults with polymyositis and dermatomyositis.

18 imately 25% of patients with polymyositis or dermatomyositis.

19 enes are very strongly associated with adult dermatomyositis.

20 h juvenile idiopathic arthritis and juvenile dermatomyositis.

21 the 198 developed cancer after diagnosis of dermatomyositis.

22 d in serum of patients with polymyositis and dermatomyositis.

23 is of perifascicular muscle fibre atrophy in dermatomyositis.

24 atory myopathy, and the typical skin rash of dermatomyositis.

25 ammatory myopathies such as polymyositis and dermatomyositis.

26 flammatory demyelinating polyneuropathy, and dermatomyositis.

27 er inclusion body myositis, polymyositis, or dermatomyositis.

28 wide association study has been performed in dermatomyositis.

29 a differentiation-associated gene 5-positive dermatomyositis.

30 the diagnostic utility of autoantibodies in dermatomyositis.

31 ties between muscle and skin inflammation in dermatomyositis.

32 an important role in systemic sclerosis and dermatomyositis.

33 s a disease activity marker specifically for dermatomyositis.

34 e all manifestations of skin inflammation in dermatomyositis.

35 ifestations, and therapy for skin disease in dermatomyositis.

36 ad in regions of muscle fiber abnormality in dermatomyositis.

37 ans independently scored 10 children (9 with dermatomyositis, 1 with polymyositis; ages 4-15 years) t

38 d 3 pairs of monozygotic twins with juvenile dermatomyositis, 11 families with other siblings or rela

39 tigen in the human connective tissue disease dermatomyositis [14,15].

40 erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eight had ankylosin

41 erythematosus (3.06 [95% CI 1.78-4.90]) and dermatomyositis (2.64 [95% CI 0.86-6.17]) but not for sy

42 h to allow separate statistical analysis (47 dermatomyositis, 223 controls).

43 was characterized by a higher proportion of dermatomyositis (69% of adult Mestizos versus 35% of adu

44 In dermatomyositis, a multiorgan disease, evidence exists t

45 ells contribute to the pathogenesis of adult dermatomyositis, a photoinduced autoimmune skin disease.

46 association of this polymorphism with adult dermatomyositis, a photosensitive disease that exhibits

47 Patients with juvenile dermatomyositis, a systemic autoimmune disease, displaye

48 be organized under two headings--amyopathic dermatomyositis (ADM) and classic dermatomyositis (CDM).

49 who developed classic cutaneous findings of dermatomyositis along with proximal muscle weakness and

50 e frequency of the -308A allele was 0.26 for dermatomyositis and 0.14 for controls (p = 0.014).

51 Fifty adult patients with dermatomyositis and 239 healthy, race-matched controls w

52 ion may influence the relative prevalence of dermatomyositis and anti-Mi-2 autoantibodies in the US.

53 In both dermatomyositis and Duchenne dystrophy, C5-b9 deposits c

54 ment-induced microangiopathy is important in dermatomyositis and in the rare disorder, necrotizing my

55 ears, with particular focus on polymyositis, dermatomyositis and inclusion body myositis.

56 Most data for treatment of dermatomyositis and juvenile dermatomyositis are from an

57 n found abundantly in muscle tissue of adult dermatomyositis and juvenile dermatomyositis.

58 alpha, are present in substantial numbers in dermatomyositis and may account for most of the cells pr

59 ime of onset with the relative prevalence of dermatomyositis and myositis autoantibodies in 380 patie

60 All patients with dermatomyositis and polymyositis (> or =15 years old) we

61 Dermatomyositis and polymyositis are associated with can

62 Dermatomyositis and polymyositis are treatable disorders

63 ratios (SIR) for individual cancer sites for dermatomyositis and polymyositis separately, using natio

64 syndromes of chronic inflammatory myopathy (dermatomyositis and polymyositis) may have in certain in

65 In both dermatomyositis and polymyositis, risk of malignant dise

66 re is increasing evidence of autoimmunity in dermatomyositis and polymyositis, with strong correlatio

67 nd, placebo-controlled therapeutic trials of dermatomyositis and polymyositis.

68 of specific cancer types in individuals with dermatomyositis and polymyositis.

69 tissues in patients with SS from those with dermatomyositis and provide a relative weighting of the

70 In individual patients with dermatomyositis and some with polymyositis, a blood type

71 fundamental mechanistic differences between dermatomyositis and subacute cutaneous lupus erythematos

72 Children and adolescents with juvenile dermatomyositis and systemic lupus erythematosus also ex

73 tibodies found in the serum of patients with dermatomyositis and systemic lupus erythematosus, is rap

74 nous cyclophosphamide in refractory juvenile dermatomyositis and tacrolimus ointment for the dermatol

75 erstanding of autoantibodies associated with dermatomyositis and the autoimmune necrotizing myopathie

76 r with autoantibodies found in patients with dermatomyositis and the autoimmune necrotizing myopathie

77 genetics of children affected with juvenile dermatomyositis and the impact these genes have on disea

78 Advances in dermatomyositis and the juvenile idiopathic inflammatory

79 rproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythe

80 tities, but is primarily made up of juvenile dermatomyositis and, to a lesser degree, juvenile polymy

81 ith systemic illnesses (lupus erythematosus, dermatomyositis), and the skin changes of potentially fa

82 r siblings or relatives with polymyositis or dermatomyositis, and 2 families with inclusion body myos

83 ents with systemic sclerosis, 1 patient with dermatomyositis, and a healthy volunteer were scanned us

84 ific information from children with juvenile dermatomyositis, and includes pertinent data from adults

85 mes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are system

86 on inflammatory myopathies are polymyositis, dermatomyositis, and inclusion body myositis.

87 roup of diseases that includes polymyositis, dermatomyositis, and inclusion body myositis.

88 i myopathy, nemaline myopathy, polymyositis, dermatomyositis, and inclusion body myositis].

89 Systemic lupus erythematosus, juvenile dermatomyositis, and juvenile localized scleroderma stan

90 cirrhosis, Sjogren syndrome, systemic lupus, dermatomyositis, and neonatal lupus.

91 with inclusion-body myositis, polymyositis, dermatomyositis, and neurogenic muscle atrophy, but it i

92 ce of systemic lupus erythematosus, juvenile dermatomyositis, and other primary systemic vasculitides

93 antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sjogren's syndrome.

94 sitis (anti-SAE autoantibodies) and juvenile dermatomyositis (anti-p155/140 autoantibodies) (anti-MJ

95 ntibodies have been described in adult-onset dermatomyositis (anti-SAE autoantibodies) and juvenile d

96 or treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case

97 ients with HL, sensorimotor neuropathies and dermatomyositis are more frequent in NHL.

98 phil cytoplasmic antibodies+ vasculitis, and dermatomyositis are noteworthy but must be interpreted w

99 histocompatibility complex in early juvenile dermatomyositis are reported.

100 Inclusion body myositis, polymyositis, and dermatomyositis are three distinct categories of inflamm

101 articularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulat

102 be an important part of the pathogenesis of dermatomyositis, as it appears to be in systemic lupus e

103 erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferono

104 verse effects related to ipilimumab therapy, dermatomyositis associated with this agent has not previ

105 sequenced peptides eluted from the juvenile dermatomyositis-associated class II allele HLA-DQalpha1*

106 effective for the cutaneous complications of dermatomyositis but has been helpful in other extramuscu

107 available for evaluating the skin disease of dermatomyositis, but there is a need for new effective t

108 the reversibility of microvascular damage in dermatomyositis by intravenous immune globulin which app

109 amyopathic dermatomyositis (ADM) and classic dermatomyositis (CDM).

110 tion of -308A and HLA-DR3 in Caucasians with dermatomyositis compared to controls.

111 5) dermatopulmonary syndrome is a subset of dermatomyositis defined by specific clinical features an

112 are certainly effective in polymyositis and dermatomyositis despite the lack of randomized controlle

113 ing patients with polymyositis (PM) (n=114), dermatomyositis (DM) (n=102), myositis associated with a

114 l muscle metabolism in vivo in patients with dermatomyositis (DM) and polymyositis (PM) in order to e

115 c acidosis and stroke-like episodes (MELAS), dermatomyositis (DM) and polymyositis (PM) using pairwis

116 non-inflammatory or dystrophic controls, two dermatomyositis (DM) and two polymyositis (PM) patients

117 ts have confirmed that polymyositis (PM) and dermatomyositis (DM) are not genetically identical disea

118 have estimated that up to 20% of adults with dermatomyositis (DM) have calcinosis, which can lead to

119 Juvenile dermatomyositis (DM) is a chronic inflammatory myopathy

120 Dermatomyositis (DM) is a rare multisystem autoimmune di

121 Juvenile dermatomyositis (DM) is an autoimmune disease of childho

122 Dermatomyositis (DM) is an autoimmune disease, which is

123 Except when the diagnosis of juvenile dermatomyositis (DM) is in doubt, a case has not been ma

124 The accumulated mucin in non-Gottron's dermatomyositis (DM) lesions is primarily chondroitin-4-

125 fication of novel autoantibodies in juvenile dermatomyositis (DM) may have etiologic and clinical imp

126 ts with polymyositis (PM) than in those with dermatomyositis (DM) or other myositis syndromes.

127 (PM) and adults and children with refractory dermatomyositis (DM) were enrolled.

128 Sera from 20 adult patients with dermatomyositis (DM) were screened for autoantibodies.

129 before and after therapy from patients with dermatomyositis (DM) who improved and patients with incl

130 vidence points toward an association between dermatomyositis (DM) with malignancy.

131 -like modifier, and its enzymatic pathway in dermatomyositis (DM), an autoimmune disease primarily in

132 f the diverse entities of polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM),

133 ), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), and normal or disease controls.

134 symptom onset and the prevalence of juvenile dermatomyositis (DM), compared to juvenile polymyositis

135 ysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and non-myopathic muscl

136 rs of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treat

137 To properly evaluate therapies for cutaneous dermatomyositis (DM), it is essential to administer an o

138 and 15 muscle samples from 44 patients with dermatomyositis (DM), polymyositis (PM), inclusion body

139 immune inflammatory muscle disorders include Dermatomyositis (DM), Polymyositis (PM), Necrotizing Myo

140 For Caucasian patients with dermatomyositis (DM), the Gm 3 23 5,13 phenotype was a r

141 atients at the time of diagnosis of juvenile dermatomyositis (DM), to compare the RANKL:osteoproteger

142 stituents of muscle inflammation in juvenile dermatomyositis (DM).

143 tained from children diagnosed with juvenile dermatomyositis (DM).

144 f low-producing MBL polymorphisms with adult dermatomyositis (DM).

145 lung disease and either polymyositis (PM) or dermatomyositis (DM).

146 nificance of the cutaneous manifestations of dermatomyositis (DM).

147 autoantibody is specifically associated with dermatomyositis (DM).

148 eases they were designed to treat, including dermatomyositis (DM).

149 found in a distinct subset of patients with dermatomyositis (DM).

150 e" is a candidate biomarker in patients with dermatomyositis (DM).

151 n implicated in the pathogenesis of juvenile dermatomyositis (DM).

152 To our knowledge, drug-induced dermatomyositis from ipilimumab has not previously been

153 y technology may also be used to distinguish dermatomyositis from the other inflammatory myopathies,

154 In dermatomyositis, genes induced by interferon-alpha/beta

155 ls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease, Hashimoto thyroiditis,

156 y of the -308A allele was 0.27 in the entire dermatomyositis group, versus 0.14 in the controls (p =

157 tion of the heterogeneity of skin disease in dermatomyositis has already provided evidence that clini

158 e conceptual model of the pathophysiology of dermatomyositis has been based on work extending back ov

159 Type I interferon activity in juvenile dermatomyositis has been demonstrated by both global gen

160 Dermatomyositis has been linked to cancer, particularly

161 Dermatomyositis has been modeled as an autoimmune diseas

162 lesions of patients with cutaneous lupus and dermatomyositis has provided valuable information about

163 Patients with dermatomyositis have a high rate of malignancy.

164 classification criteria for polymyositis and dermatomyositis have been suggested by a number of inves

165 evidence that patients with polymyositis and dermatomyositis have specific clinico-serological profil

166 dies; myovasculopathies, including childhood dermatomyositis; immune polymyopathies, active myopathie

167 Studies in adults with polymyositis and dermatomyositis implicate interleukin-1alpha, transformi

168 MBL variants were over-represented in adult dermatomyositis in a dose-responsive fashion (p=0.0002).

169 allele was positively associated with adult dermatomyositis in a dose-responsive fashion (p=0.0004),

170 adverse events and consider drug-associated dermatomyositis in the differential diagnosis in patient

171 utoantibodies preferentially associated with dermatomyositis include those recognizing Mi-2, MDA5, TI

172 new insights into the disease mechanisms of dermatomyositis, inclusion body myositis, and polymyosit

173 specific response in muscle in patients with dermatomyositis, inclusion body myositis, and polymyosit

174 ing intravenous immunoglobulin in refractory dermatomyositis, indicated benefit.

175 Although evidence remains strong that dermatomyositis is a disorder with an early involvement

176 Dermatomyositis is a microangiopathy affecting skin and

177 Dermatomyositis is a systemic disorder and whereas the s

178 Dermatomyositis is an inflammatory disorder of muscle af

179 We have previously shown that juvenile dermatomyositis is associated with the HLA-DQA1*0501 all

180 We conclude that: perifascicular atrophy in dermatomyositis is consistently associated with focal mi

181 e weakness in patients with polymyositis and dermatomyositis is due to autoimmune and inflammatory pr

182 rization of the type 1 interferon pathway in dermatomyositis is leading down a path of genomic medici

183 Dermatomyositis is one of the idiopathic inflammatory my

184 The pathogenesis of adult dermatomyositis is reviewed here, with particular attent

185 Our results provide evidence that dermatomyositis is strongly associated with a wide range

186 Juvenile dermatomyositis is the most common of the idiopathic inf

187 nective-tissue diseases, especially juvenile dermatomyositis (JDM) and systemic sclerosis; however, l

188 Juvenile dermatomyositis (JDM) is a multisystem autoimmune diseas

189 Juvenile dermatomyositis (JDM) is an immune-mediated inflammatory

190 radiation exposure 1 month prior to juvenile dermatomyositis (JDM) may trigger the onset of disease.

191 Juvenile dermatomyositis (JDM), the most common pediatric inflamm

192 d have been found in high levels in juvenile dermatomyositis (JDM), which may account the frequency o

193 n how to assess the many aspects of juvenile dermatomyositis (JDM).

194 develop in 20-40% of children with juvenile dermatomyositis (juvenile DM), contributing to disease m

195 ematosis, Wegener's granulomatosis, juvenile dermatomyositis, juvenile scleroderma and autoinflammato

196 a, mixed connective tissue disease, juvenile dermatomyositis, juvenile spondyloarthropathy and system

197 ion has now been recognized in patients with dermatomyositis-like disease.

198 fferent pathways of complement activation in dermatomyositis, lupus nephritis, and necrotic muscle fi

199 iption and classification of skin disease in dermatomyositis may allow the clinician to predict more

200 se, immunotherapies to better treat juvenile dermatomyositis may become available in the future.

201 AK-RNA interference was performed in IBM and dermatomyositis mesoangioblasts.

202 egulated pathological pathway genome-wide in dermatomyositis muscle and blood.

203 In contrast, dermatomyositis muscle shows a dominant type I IFN patte

204 e that ISG15, which is highly upregulated in dermatomyositis muscle, does not appear to play a key ro

205 interferons alpha and beta, are prominent in dermatomyositis muscle.

206 their inducible products are upregulated in dermatomyositis muscle.

207 econd-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton my

208 lt patients with polymyositis (PM; n = 134), dermatomyositis (n = 129), or other CTDs (predominantly

209 jogren's syndrome (n = 30), polymyositis and dermatomyositis (n = 30), and progressive systemic scler

210 yositis and of an IFN-alpha/beta response in dermatomyositis, neither of which was previously describ

211 ith the relative proportion of patients with dermatomyositis (odds ratio [OR] 2.3, 95% confidence int

212 for our understanding of muscle pathology in dermatomyositis of both adults and children.

213 We identified 618 cases of dermatomyositis, of whom 198 had cancer.

214 Ninety-six patients with adult-onset dermatomyositis or polymyositis had a baseline assessmen

215 muscle function in patients with established dermatomyositis or polymyositis receiving chronic medica

216 or rheumatoid arthritis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of

217 itis patients but in only 1/28 patients with dermatomyositis or polymyositis.

218 l haplotype; however, African Americans with dermatomyositis or with anti-Jo-1 autoantibodies shared

219 temic disease such as lupus erythematosus or dermatomyositis, or be an early symptom of a rare group

220 scular complement deposition is a feature of dermatomyositis pathology but the trigger for complement

221 In the dermatomyositis patient, the en face D-OCT images showed

222 from that of p155 antibody-negative juvenile dermatomyositis patients (P = 0.003).

223 antigenic target on the endothelial cell in dermatomyositis patients and the pathogenic role of the

224 In adult dermatomyositis patients homozygous for the wild-type TN

225 In adult dermatomyositis patients with one variant TNFalpha-308 A

226 Juvenile dermatomyositis patients with p155 autoantibody had a bi

227 tor-alpha synthesis is increased in juvenile dermatomyositis patients with the tumor necrosis factor-

228 ications for systemic and malignancy risk in dermatomyositis patients, and that there may be several

229 in the same 10, as well as in 40 additional dermatomyositis patients, we searched for vascular depos

230 myositis than in responsive polymyositis and dermatomyositis patients.

231 nd resistin have been detected in tissues of dermatomyositis patients.

232 In juvenile dermatomyositis, peptides from human skeletal myosin pla

233 with a subset of patients with polymyositis/dermatomyositis (PM/DM) complicated by interstitial lung

234 whether sera from patients with polymyositis/dermatomyositis (PM/DM) with or without interstitial lun

235 -55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selection of SSc,

236 , 121 with scleroderma, 86 with polymyositis/dermatomyositis [PM/DM]) and 248 Italian patients with a

237 sus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or scleroderma wh

238 The inflammatory muscle diseases dermatomyositis, polymyositis and inclusion body myositi

239 ell into the typical IIM subclassifications: dermatomyositis, polymyositis and inclusion body myositi

240 pathies (IIMs) are typically subdivided into dermatomyositis, polymyositis and inclusion body myositi

241 esoangioblasts isolated from samples of IBM, dermatomyositis, polymyositis, and control muscles were

242 the results of recent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myosit

243 muscle cells in the inflammatory myopathies (dermatomyositis, polymyositis, and inclusion body myosit

244 iopathic inflammatory myopathies, comprising dermatomyositis, polymyositis, and inclusion body myosit

245 iated into three major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myosit

246 BM patient sera, whereas their prevalence in dermatomyositis, polymyositis, and other neuromuscular d

247 Classification systems of dermatomyositis, polymyositis, and the other idiopathic

248 arison, 2/15 (14%) age-matched patients with dermatomyositis, polymyositis, or necrotizing myopathy,

249 ritis; lupus; scleroderma; Sjogren Syndrome; dermatomyositis/polymyositis; unspecified/mixed CTD; oth

250 nisone plus methotrexate achieved a juvenile dermatomyositis PRINTO 20 improvement (p=0.0228).

251 proportion of patients achieving a juvenile dermatomyositis PRINTO 20 level of improvement (20% impr

252 ic systemic lupus erythematosus and juvenile dermatomyositis, remain life-threatening.

253 d Musculoskeletal and Skin Diseases Juvenile Dermatomyositis Research Registry and the National Pedia

254 py is essential, since both polymyositis and dermatomyositis respond to immunotherapeutic agents.

255 vascular membrane attack complex deposits in dermatomyositis result from activation of the classical

256 d unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis.

257 the dermatologic manifestations of juvenile dermatomyositis seem promising.

258 ow the possibility that, for the first time, dermatomyositis skin disease can serve as a valid outcom

259 lases HDAC1/2, histone-binding proteins, the dermatomyositis-specific autoantigen Mi2beta, a polypept

260 Thirty-one of 50 dermatomyositis specimens contained C5b-9 reactive endom

261 , and the LX promoter polymorphism) in adult dermatomyositis, subacute cutaneous lupus erythematosus,

262 liminary gene expression studies in juvenile dermatomyositis, systemic lupus erythematosus, and chron

263 and specific prior autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoimmune hemolyti

264 ot observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthriti

265 an inflammatory myopathies (polymyositis and dermatomyositis), the early, widespread appearance of MH

266 ar to what is observed in human polymyositis/dermatomyositis, the mice developed a strong antinuclear

267 n understanding these mechanisms in juvenile dermatomyositis, the most common form of childhood infla

268 In juvenile dermatomyositis, the quantitative magnetic resonance ima

269 lar atrophy, and what is the relationship of dermatomyositis to systemic lupus erythematosus.

270 ols, OR = infinite; two-sided p = 0.02), but dermatomyositis was absent in cases themselves.

271 Family history of dermatomyositis was associated with NHL (7 cases vs. 0 c

272 ation, the association of these two genes in dermatomyositis was significantly less than we previousl

273 To further understand the pathophysiology of dermatomyositis, we used microarrays, computational meth

274 sms in patients with rheumatoid arthritis or dermatomyositis were analyzed by polymerase chain reacti

275 A total of 37 patients with polymyositis or dermatomyositis were randomized (19 to creatine, 18 to p

276 factor -308A polymorphism is associated with dermatomyositis, which suggests a pathophysiologic contr

277 18 years or younger with new-onset juvenile dermatomyositis who had received no previous treatment a

278 affect as many as 20% to 30% of adults with dermatomyositis, will not be addressed in this review.

279 crosis factor-alpha, more common in juvenile dermatomyositis with the tumor necrosis factor-alpha-308

280 They distinguish dermatomyositis with vascular pathology from other infla

281 juvenile idiopathic arthritis, and juvenile dermatomyositis, with special interest on strategies to